Market LIVE
Published markets; coverage varies by country
Product profile · United States

Opdivo

 ·  Patent Litigation & Settlement History ↓

Ingredientnivolumab
Application typeBLA
Application125554
Product002
Dosage formInjection
RouteIntravenous
Strength100MG/10ML (10MG/ML)
Approval date2014-12-22
Marketing statusPrescription
Status event—
ApplicantBRISTOL MYERS SQUIBB
Product source

Current GenericRadar decision

Year2028
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typePATENT
Anchor date2028-12-22
Patent anchor2028-12-22
Exclusivity anchor2027-06-22
Protection date—
First Final ANDA—
Status event—

BLA-05-02/18: Opdivo 100MG/10ML (10MG/ML); 2028 DEEP_REVIEW; anchor=2028-12-22 (PATENT). Flags: RPE_OPERATIONAL_NOT_FDA_DETERMINATION; PTE_DATE_CONFLICT:8008449; EXACT_FINAL_ANDA_NOT_SEPARATELY_RECHECKED;NO_DISQUALIFICATION_FROM_INDIRECT_BIOSIMILAR. Final operational judgment adopted; no verified=1 promotion. Update when evidence is found.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
Orphan Exclusivity Exp. Date—2031-04-13————Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
BLA_PATENT_EXCLUSIVITY_REVIEW—BUSINESS_CLASSIFICATION_WITH_CONDITIONSBLA-05-02/18: Opdivo 100MG/10ML (10MG/ML); 2028 DEEP_REVIEW; anchor=2028-12-22 (PATENT). Flags: RPE_OPERATIONAL_NOT_FDA_DETERMINATION; PTE_DATE_CONFLICT:8008449; EXACT_FINAL_ANDA_NOT_SEPARATELY_RECHECKED;NO_DISQUALIFICATION_FROM_INDIRECT_BIOSIMILAR. Final operational judgment adopted; no verified=1 promotion. Update when evidence is found.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.